The global breast cancer screening market size was US$ 5.1 billion in 2021. The global breast cancer screening market is forecast to grow to US$ 9.43 billion by 2030 by growing at a compound annual growth rate (CAGR) of 8.1% during the forecast period from 2022 to 2030.

Factors Influencing the Market

Breast cancer is among the most commonly seen cancer globally. The disease is mainly affecting women between the age of 50-70 years. In addition, the report by the American Cancer Society says that around 280,000 new breast cancer cases are forecast to be diagnosed in 2021. Thus, the growing prevalence of breast cancer will drive the breast cancer screening market forward.

Rapidly growing awareness related to the signs and symptoms of breast cancer, and the need for early screening and diagnosis will contribute to the growth of the breast cancer screening market during the study period.

The growing number of initiatives by governments worldwide will surge the growth of the breast cancer screening market. Other factors like increasing healthcare expenditure and growing individual spending on healthcare will contribute to the growth of the market.

Technological advancements will always remain a significant factor boosting the growth of the market. For instance, the launch of direct-to-consumer (DTC) testing by 23andMe (2018) is likely to gain traction during the forecast period.

The growing knowledge about insurance coverage and the wide range of affordable and convenient screening tests like physical tests, laboratory tests, imaging tests, and genetic tests will influence the growth of the market.

COVID-19 Impact Analysis

The global COVID-19 pandemic abruptly laid down the burden on the healthcare segment. The global healthcare industry witnessed the need to look over the COVID-19 emergency and postpone other cases until necessary. As a result, it halted the demand for breast cancer screening devices. In addition, the demand for breast cancer diagnosis, including mammography screening and treatment procedures, declined as people avoided visiting crowded places or places having high chances of virus transmission. Thus, global breast cancer screening witnessed drastic change due to the pandemic.

Regional Analysis

North America is forecast to dominate the global breast cancer screening market due to the high healthcare expenditure and increasing prevalence of breast cancer. In addition, the growing adoption of advanced technology and the contribution of favorable insurance policies will contribute to the growth of the breast cancer screening market.

The Asia-Pacific breast cancer screening market is forecast to register significant growth due to growing healthcare expenditure, rising healthcare infrastructure, and increasing cases of breast cancer.

Competitors in the Market

Siemens Healthcare
Allengers Infotech
Hologic, Inc.
Myriad Genetics
Metabolomic Technologies Inc.
Biocrates LifeSciences AG
A&G Pharmaceuticals
Provista Diagnostics, Inc.
Roche Diagnostics
POC Medical Systems
BioTime, Inc.
General Electric Company
Quest Diagnostics
Agendia NV
OncoCyte Corporation
Other prominent Players
Market Segmentation

The global breast cancer screening market segmentation focuses on Test, End-User, and Region.

The breast cancer screening market has been segmented based on test type

Physical Tests
Laboratory Tests
Imaging Tests
Genetic Tests
The breast cancer screening market has been segmented based on the end-user

Research Labs
Cancer Institutes
Diagnostic Centers
Others
The breast cancer screening market has been segmented based on the region

North America
The U.S.
Canada
Mexico
Europe
Western Europe
The UK
Germany
France
Italy
Spain
Rest of Western Europe
Eastern Europe
Poland
Russia
Rest of Eastern Europe
Asia Pacific
China
India
Japan
Australia & New Zealand
ASEAN
Rest of Asia Pacific
Middle East & Africa (MEA)
UAE
Saudi Arabia
South Africa
Rest of MEA
South America
Brazil
Argentina
Rest of South America